L-Theanine Relieves Positive, Activation, and Anxiety Symptoms in Patients With Schizophrenia and Schizoaffective Disorder: An 8-Week, Randomized, Double-Blind, Placebo-Controlled, 2-Center Study
The DOI matches its Crossref record; the references it cites are not checked yet.
Abstract
Objective L-theanine is a unique amino acid present almost exclusively in the tea plant. It possesses neuroprotective, mood-enhancing, and relaxation properties. This is a first study designed to evaluate the efficacy and tolerability of L-theanine augmentation of antipsychotic treatment of patients with chronic schizophrenia and schizoaffective disorder. Method 60 patients with DSM-IV schizophrenia or schizoaffective disorder participated in an 8-week, double-blind, randomized, placebo-controlled study. 400 mg/d of L-theanine was added to ongoing antipsychotic treatment from February 2006 until October 2008. The outcome measures were the Positive and Negative Syndrome Scale (PANSS), the Hamilton Anxiety Rating Scale (HARS), the Cambridge Neuropsychological Test Automated Battery (CANTAB) for neurocognitive functioning, and additional measures of general functioning, side effects, and quality of life. Results 40 patients completed the study protocol. Compared with placebo, L-theanine augmentation was associated with reduction of anxiety (P = .015; measured by the HARS scale) and positive (P = .009) and general psychopathology (P Conclusions L-theanine augmentation of antipsychotic therapy can ameliorate positive, activation, and anxiety symptoms in schizophrenia and schizoaffective disorder patients. Further long-term studies of L-theanine are needed to substantiate the clinically significant benefits of L-theanine augmentation.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Ritsner and colleagues found in a double-blind randomized placebocontrolled clinical trial recruiting 60 patients diagnosed with chronic schizophrenia and schizoaffective disorder that L-theanine supplementation for 8 weeks combined with the respective ongoing antipsychotic treatment was able to significantly reduce anxiety and significantly improve general psychopathological scores [25].”
From Psychotropic effects of L-theanine and its clinical properties: from the management of anxiety and stress to a potential use in schizophrenia (2019) · cites this paper as [25]
In the citing paper
“Ritsner and colleagues found in a double-blind randomized placebocontrolled clinical trial recruiting 60 patients diagnosed with chronic schizophrenia and schizoaffective disorder that L-theanine supplementation for 8 weeks combined with the respective ongoing antipsychotic treatment was able to significantly reduce anxiety and significantly improve general psychopathological scores [25].”
From Psychotropic effects of L-theanine and its clinical properties: from the management of anxiety and stress to a potential use in schizophrenia (2019) · cites this paper as [25]
In the citing paper
“Such findings were obtained through the employment of several validated psychometric tools, including the Hamilton Anxiety Rating Scale (HARS), Tension Anxiety Scores, Pittsburgh Sleep Quality Index (PSQI), Positive and Negative Syndrome Scale (PANSS) [24,25], and others.”
From Psychotropic effects of L-theanine and its clinical properties: from the management of anxiety and stress to a potential use in schizophrenia (2019) · cites this paper as [25]
In the citing paper
“The authors emphasized in both studies the beneficial effects of L-theanine alongside its safety and good tolerance at daily doses of 400 mg [25,32].”
From Psychotropic effects of L-theanine and its clinical properties: from the management of anxiety and stress to a potential use in schizophrenia (2019) · cites this paper as [25]
In the citing paper
“On the other hand, findings from Ritsner and colleagues found no evidence that L-THE (400 mg/day) improved cognitive function, attention or learning [65].”
From l-Theanine as a Functional Food Additive: Its Role in Disease Prevention and Health Promotion (2016) · cites this paper as [65]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Citations
The citation lists are queued
They are fetched later and appear here then.
References 58 · Cited by 74
Metadata
- Authors
- Ritsner, M. S., Miodownik, C., Ratner, Y., Shleifer, T., Mar, M., Pintov, L., & Lerner, V.
- Affiliations
- Technion – Israel Institute of Technology (IL)
- Corresponding author
- Lerner, Vladimir
- ORCID
- Lerner, Vladimir
- Venue
- The Journal of Clinical Psychiatry
- Publisher
- Physicians Postgraduate Press, Inc
- Published
- 2010-11-30
- Volume
- 72
- Issue
- 01
- Pages
- 34-42
- ISSN
- 0160-6689 (ISSN-L)
- OpenAlex
- W2033079512
- Cited by
- 74
- References
- 58
- Citations by year
- 2026: 2 · 2025: 4 · 2024: 10 · 2023: 4 · 2022: 3 · 2021: 3 · 2020: 5 · 2019: 4 · 2018: 5 · 2017: 6 · 2016: 5 · 2015: 5 · 2014: 5 · 2013: 4 · 2012: 3
- FWCI
- 2.84
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Amino Acid Enzymes and Metabolism
- Keywords
- theanine, schizophrenia, schizoaffective disorder, antipsychotic augmentation, anxiety symptoms, positive symptoms, neurocognitive function, tolerability, quality of life
- MeSH terms
- Adult, Cognition Disorders, Double-Blind Method, Drug Therapy, Combination, Female, Glutamates, Humans, Male, Middle Aged, Neuropsychological Tests, Placebos, Psychotic Disorders, Schizophrenia, Schizophrenic Psychology, Antipsychotic Agents, Treatment Outcome, Neuroprotective Agents
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: L-Theanine Relieves Positive, Activation, and Anxiety Symptoms in Patients With Schizophrenia and Schizoaffective Disorder: An 8-Week, Randomized, Double-Blind, Placebo-Controlled, 2-Center Study. https://app.cochat.ai/papers/10.4088/jcp.09m05324gre
- The paper
- Ritsner, M. S., Miodownik, C., Ratner, Y., Shleifer, T., Mar, M., Pintov, L., & Lerner, V. (2011). L-Theanine Relieves Positive, Activation, and Anxiety Symptoms in Patients With Schizophrenia and Schizoaffective Disorder: An 8-Week, Randomized, Double-Blind, Placebo-Controlled, 2-Center Study. The Journal of Clinical Psychiatry. https://doi.org/10.4088/jcp.09m05324gre
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.